Search results
Results From The WOW.Com Content Network
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. [ 3 ] [ 4 ] Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals , focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies.
Alcon is the world's largest and most profitable eye care company, Novartis said in a statement, with 2009 annual sales of $6.5 billion and net income of $2 billion.
Alcon: At the time Novartis bought Alcon, they had annual sales of $6.5 billion and a net income of $2 billion. [128] In April 2019, Novartis completed the spin-off of Alcon as a separate commercial entity. [73] Sandoz: As of 2013, Sandoz has been recognized as the world's second-largest generic drug company.
Shares of Novartis (NVS) soared higher on Wednesday, after the Swiss drug maker finally obtained the remaining outstanding shares of Alcon (ACL) for $12.9 billion. Novartis had been trying to gain ...
Ciprodex, owned by Alcon Laboratories, Inc., is protected by multiple patents and will be restricted from generic manufacturing until 2025. [6] [7] Ciprodex is the number 1 topical antibiotic ear drop prescribed since 2007 by ENTs and pediatricians.
More than two years after beginning the acquisition process, Swiss pharmaceutical company Novartis (NVS) said Thursday that it has finally completed the purchase of a 77% majority stake in U.S ...
The European Commission has approved the intravitreal eye injection Jetrea, produced by Novartis eye care subsidiary Alcon, for treating vitreomacular traction in the European Union. The disease ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.